

REMARKS

The Amendment is submitted to remove multiple dependant claims. No prohibited new matter has been added by way of this amendment. Examination of the claims as amended is respectfully requested.


Except for issue fees payable under 37 CFR §1.18, the commissioner is hereby authorized by this paper to charge any additional fees during the pendency of this application including fees due under 37 CFR §1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 CFR §1.136(a)(3).

If the Examiner has any further questions relating to this Amendment or to the application in general, he or she is respectfully requested to contact the undersigned by telephone so that allowance of the present application may be expedited.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Date: **April 23, 2003**



Michael S. Tuscan
Reg. No. 43,210

Customer No. 009629
MORGAN, LEWIS & BOCKIUS, LLP
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
(202) 739-3000

APPENDIX

The following claims were amended above.

28. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin polypeptide or fragment thereof is raised against an immunoglobulin light-chain.
29. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin polypeptide or fragment thereof opsonizes amyloid fibrils in amyloid deposits.
30. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin polypeptide or fragment thereof is a monoclonal antibody.
37. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin fragment is a Fv fragment, Fab fragment, F(ab'') fragment, F(ab')₂ fragment, or SvFv fragment.
38. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin is a single chain antibody.
39. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin has cross-isotype reactivity.
40. The method of [~~any one of claims 23-25,~~ claim 24], wherein the immunoglobulin is reactive with a non-light chain amyloid.

42. The method of [~~any one of claims 23-25,~~ claim 24, wherein the patient is a human.

43. The method of [~~any one of claims 23-25,~~ claim 24, wherein the immunoglobulin polypeptide or fragment thereof is reactive with an amyloid fibril other than the amyloid fibril or component or precursor thereof, against which the immunoglobulin polypeptide or fragment thereof was raised.

44. The method of [~~any one of claims 23-25,~~ claim 24, wherein more than one immunoglobulin polypeptide or fragment thereof is administered to the patient.

45. The method of [~~any one of claims 23-25,~~ claim 24, wherein the immunoglobulin polypeptide or fragment thereof is administered with a carrier.